Hospital Mater Dei (BSP:MATD3) ROCE %: 12.03% (As of Mar. 2026)


BSP:MATD3 Hospital Mater Dei SA BSP:MATD3
83 GF Score
Price R$4.84
GF Value R$5.88
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Hospital Mater Dei ROCE %?

Hospital Mater Dei BSP:MATD3 +2.98% 83 ROCE % is 12.03% as of Mar. 2026. GuruFocus rates BSP:MATD3 with a GF Score™ of 83/100 and a GF Value™ of R$5.88 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hospital Mater Dei's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.03%.

Hospital Mater Dei  (BSP:MATD3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hospital Mater Dei ROCE % Related Terms

Hospital Mater Dei ROCE % Historical Data

* Premium members only.

The historical data trend for Hospital Mater Dei's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hospital Mater Dei ROCE % Chart

Hospital Mater Dei Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only 13.38 9.97 9.87 -6.18 11.40

Hospital Mater Dei Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.55 11.48 12.10 12.35 12.03
BSP:MATD3
83GF Score
Hospital Mater Dei SA BSP:MATD3
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hospital Mater Dei ROCE % Calculation

Hospital Mater Dei's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=438.516/( ( (4340.852 - 467.424) + (4312.889 - 491.106) )/ 2 )
=438.516/( (3873.428+3821.783)/ 2 )
=438.516/3847.6055
=11.40 %

Hospital Mater Dei's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=459.2/( ( (4312.889 - 491.106) + (4334.97 - 521.207) )/ 2 )
=459.2/( ( 3821.783 + 3813.763 )/ 2 )
=459.2/3817.773
=12.03 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.03% mean?
Hospital Mater Dei (BSP:MATD3) has a ROCE % of 12.03% as of Mar. 2026.
Is Hospital Mater Dei's ROCE % too high?
Hospital Mater Dei's current ROCE % is 12.03%. The Healthcare Providers & Services industry median ROCE % is 6.39. Hospital Mater Dei's value of 12.03% is 88.3% above this industry median. Overall, Hospital Mater Dei has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hospital Mater Dei's ROCE % compare to HCA and THC?
Hospital Mater Dei's ROCE % of 12.03% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.39. Hospital Mater Dei's value of 12.03% is 88.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.39, based on 644 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hospital Mater Dei's current ROCE % of 12.03% is 88.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hospital Mater Dei's current ROCE % is 12.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital Mater Dei stock overvalued right now?
Based on GuruFocus' analysis, Hospital Mater Dei (BSP:MATD3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$5.88, compared to a current price of R$4.84 — trading 17.7% below its estimated fair value. The current ROCE % is 12.03% and 88.3% above the Healthcare Providers & Services industry median of 6.39. Hospital Mater Dei's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Hospital Mater Dei (BSP:MATD3), the current ROCE % is 12.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hospital Mater Dei (BSP:MATD3) Overvalued in 2026?

Based on GuruFocus' analysis, Hospital Mater Dei stock appears to be undervalued. The current stock price of R$4.84 is trading 17.7% below its estimated GF Value™ of R$5.88. GuruFocus considers Hospital Mater Dei to be Modestly Undervalued.

Key valuation signals for BSP:MATD3:

  • ROCE %: 12.03%
  • GF Value™: R$5.88 vs. price of R$4.84 (17.7% below fair value)
  • GF Score™: 83/100 with 3 warning signs
  • Industry Position: 88.3% above the Healthcare Providers & Services median

No single metric tells the full story. See the BSP:MATD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hospital Mater Dei Business Description

Address Rua Mato Grosso, No. 1, 100, Bairro Santo Agostinho, Belo Horizonte, MG, BRA, 30.190-081
Hospital Mater Dei SA is an integrated healthcare ecosystem that provides hospital and oncological services. The company provides a wide range of healthcare services, including hospitalizations, surgeries, oncology treatments, medical appointments, and diagnostic exams.
83GF Score

Get the complete analysis for BSP:MATD3

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$4.84
Price
R$5.88
GF Value